Log In
Print this Print this

Lantus XR, Toujeo, insulin glargine (formerly U300)

  Manage Alerts
Collapse Summary General Information
Company Sanofi
Description300 units/mL formulation of insulin glargine, a synthetic, sustained-release, subcutaneous insulin analog
Molecular Target Insulin receptor (INSR)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type I and Type II diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation U.S. - Standard Review (Treat Type I and Type II diabetes);
EU - Standard Review (Treat Type I and Type II diabetes)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today